TY - JOUR
T1 - Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination
AU - Kawada, Junji
AU - Wada, Hisashi
AU - Isobe, Midori
AU - Gnjatic, Sacha
AU - Nishikawa, Hiroyoshi
AU - Jungbluth, Achim A.
AU - Okazaki, Nami
AU - Uenaka, Akiko
AU - Nakamura, Yurika
AU - Fujiwara, Shinichi
AU - Mizuno, Naoaki
AU - Saika, Takashi
AU - Ritter, Erika
AU - Yamasaki, Makoto
AU - Miyata, Hiroshi
AU - Ritter, Gerd
AU - Murphy, Roger
AU - Venhaus, Ralph
AU - Pan, Linda
AU - Old, Lloyd J.
AU - Doki, Yuichiro
AU - Nakayama, Eiichi
PY - 2012/2/1
Y1 - 2012/2/1
N2 - NY-ESO-1 is a prototypic cancer/testis antigen. In a recent phase I clinical trial, we vaccinated 13 patients bearing NY-ESO-1-expressing tumors with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and showed efficient induction of NY-ESO-1 antibody, and CD4 and CD8 T cell responses using peripheral blood from the patients. In our study, we analyzed heteroclitic serological responses in those patients after vaccination. Serological response against 11 tumor antigens including MAGE-A1, MAGE-A3, MAGE-A4, CT7/MAGEC1, CT10/MAGEC2, CT45, CT46/HORMAD1, SOX2, SSX2, XAGE1B and p53 was examined by enzyme-linked immunosorbent assay (ELISA) using sera from ten vaccinated patients. Expression of tumor antigens was determined by reverse transcription-polymerase chain reaction or immunohistochemistry. Eight of nine patients who showed antibody responses against NY-ESO-1 also showed an antibody response against at least 1 of these 11 tumor antigens after vaccination. In one patient, seven tumor antigens were recognized. Specificity analysis of the antibody response by ELISA using control recombinant proteins and synthetic peptides and by Western blot showed that the response was not against His6-tag and/or bacterial products included in a preparation of CHP-NY-ESO-1 used for vaccination. Thus, heteroclitic serological responses appear to be indicative of the overall immune response against the tumor, and their analysis could be useful for immune monitoring in cancer vaccine.
AB - NY-ESO-1 is a prototypic cancer/testis antigen. In a recent phase I clinical trial, we vaccinated 13 patients bearing NY-ESO-1-expressing tumors with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and showed efficient induction of NY-ESO-1 antibody, and CD4 and CD8 T cell responses using peripheral blood from the patients. In our study, we analyzed heteroclitic serological responses in those patients after vaccination. Serological response against 11 tumor antigens including MAGE-A1, MAGE-A3, MAGE-A4, CT7/MAGEC1, CT10/MAGEC2, CT45, CT46/HORMAD1, SOX2, SSX2, XAGE1B and p53 was examined by enzyme-linked immunosorbent assay (ELISA) using sera from ten vaccinated patients. Expression of tumor antigens was determined by reverse transcription-polymerase chain reaction or immunohistochemistry. Eight of nine patients who showed antibody responses against NY-ESO-1 also showed an antibody response against at least 1 of these 11 tumor antigens after vaccination. In one patient, seven tumor antigens were recognized. Specificity analysis of the antibody response by ELISA using control recombinant proteins and synthetic peptides and by Western blot showed that the response was not against His6-tag and/or bacterial products included in a preparation of CHP-NY-ESO-1 used for vaccination. Thus, heteroclitic serological responses appear to be indicative of the overall immune response against the tumor, and their analysis could be useful for immune monitoring in cancer vaccine.
KW - NY-ESO-1
KW - cancer testis antigen
KW - cancer vaccine
KW - heteroclitic antibody response
UR - https://www.scopus.com/pages/publications/82255191897
U2 - 10.1002/ijc.26074
DO - 10.1002/ijc.26074
M3 - Article
C2 - 21413013
AN - SCOPUS:82255191897
SN - 0020-7136
VL - 130
SP - 584
EP - 592
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 3
ER -